louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05636722: Online Self-help for Students With Suicidal Ideation
Official title: Evaluation of an Unguided Web-based Intervention for Students With Suicidal Ideation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Suicidal Ideation
Lead sponsor: University Ghent
Sponsor class: OTHER
First posted: 2022-12-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main goal of this study is to evaluate the effectiveness of an unguided web-based intervention for (college/university) students with suicidal ideation. This study will test the effectiveness by studying the effect on suicidal ideation and related outcomes (hopelessness and worrying) through a pre-post study design.


Eligibility criteria: Inclusion Criteria:

* Be student at a university or college
* Have suicidal thoughts
* ≥ 18 years old
* Have access to internet and a computer/laptop/smartphone
* Speak Dutch

Exclusion Criteria:

* /

Primary outcomes:
measure: Suicidal ideation: Beck Scale for Suicide Ideation
timeFrame: Baseline (right before the intervention)
measure: Suicidal ideation: Beck Scale for Suicide Ideation
timeFrame: posttest (6 weeks after baseline)
Secondary outcomes:
measure: Hopelessness: The Beck Hopelessness Scale, 4-item version
timeFrame: Baseline (right before the intervention)
measure: Hopelessness: The Beck Hopelessness Scale, 4-item version
timeFrame: posttest (6 weeks after baseline)
measure: Worrying: Penn State Worry Questionnaire Past Week
timeFrame: Baseline (right before the intervention)
measure: Worrying: Penn State Worry Questionnaire Past Week
timeFrame: posttest (6 weeks after baseline)
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: Flemish Centre of Expertise in Suicide Prevention, Ghent University
Study officials:
affiliation: University Ghent
name: Gwendolyn Portzky, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03361722: Interest of Tissue Oxygen Pressure (PtiO2) Monitoring to Detect a Vasospasm Post Aneurysmal Subarachnoid Hemorrhage
Official title: Interest of Tissue Oxygen Pressure (PtiO2) Monitoring to Detect a Vasospasm Post Aneurysmal Subarachnoid Hemorrhage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage, Aneurysmal
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2017-12-05
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients, hospitalized in intensive care unit and sedated, with severe aneurysmal subarachnoid hemorrhage

Brief summary: Vasospasm is a current complication after aneurysmal subarachnoid hemorrhage and often and often associated with brain ischemia. This complication is difficult to detect, because clinical examination is hardly helpful in sedated patients and the performances of transcranial doppler can only detect the spasm of middle cerebral arteries.

Tissue Oxygen Pressure (PtiO2) Monitoring allows early detection of brain oxygenation local modifications and of brain ischemia, via continuous monitoring.

This study aims to assess the performance of the tissue oxygen pressure monitoring in detecting a vasospasm post aneurysmal subarachnoid hemorrhage.


Eligibility criteria: Inclusion Criteria:

* severe aneurysmal subarachnoid hemorrhage
* patient sedated
* patient hospitalized in intensive care unit between January 2013 and August 2015
* multimodal neurologic monitoring including Tissue Oxygen Pressure and transcranial doppler

Exclusion Criteria:

* insonation impossible

Primary outcomes:
measure: Tissue Oxygen Pressure
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01337622: Gastric Residuals in Preterm Infants
Official title: Gastric Residuals in Preterm Infants (GRIP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Early Enteral Feeding Advancement
Nutrition
Preterm Infants
Lead sponsor: McMaster Children's Hospital
Sponsor class: OTHER
First posted: 2011-04-19
Enrollment: 87
Sex: ALL
Maximum age (years): 48
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Checking of gastric residuals prior to the continuation/increase of enteral feeding prolongs the time to establish full gastric feeding in the early postnatal period.


Eligibility criteria: Inclusion Criteria:

* Infants with a birth weight ≥ 1500g and \< 2000g
* Age ≤48 hours of life
* Informed, written parental consent

Exclusion Criteria:

* Antenatally recognized gastrointestinal malformation
* Major congenital anomaly
* Chromosomal anomaly
* NEC stage II
* Severe acidosis, asphyxia (pH \<7.0)
* Severe growth restriction below 3rd percentile

Primary outcomes:
measure: Time to reach full enteral feeding
timeFrame: from inclusion (during first 48h of life) until 1 month
Secondary outcomes:
measure: growth, tolerance, morbidity
timeFrame: from inclusion (during first 48h of life) until one month
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: McMaster Children's Hospital
state: Ontario
Study officials:
affiliation: McMaster University
name: Sumesh Thomas, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Singh B, Rochow N, Chessell L, Wilson J, Cunningham K, Fusch C, Dutta S, Thomas S. Gastric Residual Volume in Feeding Advancement in Preterm Infants (GRIP Study): A Randomized Trial. J Pediatr. 2018 Sep;200:79-83.e1. doi: 10.1016/j.jpeds.2018.04.072. Epub 2018 Jun 1.
Clinical trial NCT04663022: Influence of the Sensory Profile of Deaf Children With Autism Spectrum Disorders on the Outcome of Cochlear Implantation
Official title: Influence of the Sensory Profile of Deaf Children With Autism Spectrum Disorders on the Outcome of Cochlear Implantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Deafness
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2020-12-10
Enrollment: 33
Sex: ALL
Minimum age (years): 15
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population is deaf children with cochlear implant. In the first group, children must have cochlear implant and autism spectrum disorders, and in second group, children must have only cochlear implant.

Brief summary: An unpublished study conducted at Toulouse University Hospital revealed that 30% of implanted children with Autism Spectrum Disorders abandon their implant, while 70% of them keep it. The aim of this study is to evaluate the causes of this disparity, which is much greater than in children with cochlear implants without associated Autism Spectrum Disorders. Our problem is as follows: do the sensory hypersensitivity and hyposensitivity of deaf children with Autism Spectrum Disorders have an effect on the expected results after a cochlear implantation from a language and auditory reaction point of view?

Detailed description: The present study will specifically focus on the sensory profile of these children with Autism Spectrum Disorders, which could be the cause of these developmental difficulties in language and communication development.

Eligibility criteria: Inclusion Criteria:

* Deaf child with cochlear implant
* 15 months to 10 years old and 6 months old at the time of implantation
* Child with autism spectrum disorder (only for children group with autisme spectrum disorder)
* No opposition from the legal representative of the authority to participate in the study

Exclusion Criteria:

* Opposition by the legal representative of the child
* Child under legal protection

Primary outcomes:
measure: determine the sensory profile
timeFrame: inclusion visit
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital of Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Marie-Noëlle Calmels, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06363422: The Value of Epicanthoplasty on the Modification of Upper-eyelid Appearance
Official title: The Value of Epicanthoplasty on the Modification of Upper-eyelid Appearance: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patient Satisfaction
Epicanthus; Fold
Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In East Asian populations, the combination of an epicanthic fold and mono-eyelid is one of their anatomical characteristic. The epicanthic fold may diminish the aesthetic effects of eyelid cosmetic surgery, shorten the horizontal length, and affect the postoperative shape of double eyelids

Brief summary: In East Asian populations, the combination of an epicanthic fold and mono-eyelid is one of their anatomical characteristics. Misalignment of the orbicularis oculi muscle and fibrous connections leads to longitudinal tension, forming the epicanthic fold. The epicanthic fold may diminish the aesthetic effects of eyelid cosmetic surgery, shorten the horizontal length, and affect the postoperative shape of double eyelids. As upper eyelid cosmetic surgery is one of the most common cosmetic procedures in Asia, there is increasing attention on the modification of the epicanthic fold and its impact on the formation of double eyelids.


Eligibility criteria: Inclusion Criteria:

* 1: Patients who have previously undergone unsatisfactory blepharoplasty, combined with epicanthic fold issues;

  2: Underwent epicanthoplasty in this center

  3: over 18-year-old and less than 60-year-old

  4: Clinical data was comprehensive.

Exclusion Criteria:

* 1: The patient has concurrent untreated lacrimal defects, excessive eyelid skin, and other complications such as entropion and ectropion.

Primary outcomes:
measure: inter-epicanthal distance (IED)
timeFrame: preoperatively and through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai ninth people's hospital
Study officials:
affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
name: Lin Lu, PhD.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00140322: Dane County Safety Assessment (SAFE) Research Study
Official title: Dane County Safety Assessment for Elders (SAFE) Research Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Falls
Keywords: falls
injury
elderly
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
Collaborators: name: Wisconsin Department of Health and Family Services
name: University of Wisconsin, Madison
First posted: 2005-09-01
Enrollment: 455
Sex: ALL
Minimum age (years): 0
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A randomized controlled trial to assess the effectiveness of an at-home comprehensive approach to preventing falls among adults 65 years and older at high risk for falls.

Detailed description: A randomized controlled trial to assess the effectiveness of a comprehensive approach to preventing falls among adults 65 years and older at high risk for falls. This intervention includes a comprehensive health assessment in each participant's home combined with tailored risk reduction strategies such as individualized strength and balance exercises. The study is also conducting a community-based program to engage and educate physicians about fall prevention.

The goal of the study is to demonstrate a 40% decrease in fall rates. Other expected outcomes include decreased hospital and nursing home stays, improved physical function, and a decreased fear of falling.

Eligibility criteria: Inclusion Criteria: Adults age 65+, at high risk for falls, -

Exclusion Criteria: Adults \<65 years

-

Primary outcomes:
measure: Decreased fall rates
Secondary outcomes:
measure: decreased hospital and nursing home stays
measure: improved physical function
measure: decreased fear of falling
Other outcomes:
Locations:
Study officials:
affiliation: University of Wisconsin Medical School
name: Jane Mahoney, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Garbez N, Mbatchi LC, Maseda E, Luque S, Grau S, Wallis SC, Muller L, Lipman J, Roberts JA, Lefrant JY, Roger C. A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Ther Drug Monit. 2021 Dec 1;43(6):747-755. doi: 10.1097/FTD.0000000000000874.
Clinical trial NCT03491722: Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population
Official title: Evolution of Risk Factors and Revascularization Among >1 Decade Survivors After Coronary Revascularization in the Middle East
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Risk Factors AND Repeat Revascularization
Lead sponsor: Jordan Collaborating Cardiology Group
Sponsor class: OTHER
First posted: 2018-04-09
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All comers who had undergone coronary stent or bypass surgery 10 years or more prior to interview. These patients will be asked about the appearance of new cardiovascular risk factors during this period and whether they had undergone further operations or procedures to the coronary arteries, carotid arteries, lower limb arteries ir renal arteries.

Brief summary: The study will look at the cardiovascular risk factors as they arise, as well at the need for further revascularization after at least 10 years of coronary revascularization in Middle Eastern patients.

The PI will overlook the whole process. Dr Ahmad Tamari, the assistant to the PI will asses this whole process of data collection, management and manuscript drafting.

Detailed description: Middle Eastern patients aged 18 years or above presenting to cardiology service at one tertiary care center who had coronary revascularization (stent or coronary bypass surgery, i.e., index procedure) at least 10 years back, will interviewed to determine:

1. Evolution of cardiovascular risk factors in the period from index procedure to time of interview. These risk factors include; hypertension, diabetes, smoking, dyslipidemia and obesity.
2. Need for further arterial revascularization from the index procedure to time of interview.

   These arterial revascularization procedures include A. Coronary: stent and/or bypass surgery B. Carotid endarterectomy. C. peripheral arterial revascularization D. Renal artery stent.
3. Medications used at the time if interview with special emphases on the guideline-recommended medications including antiplatelet agents, beta blockers, statins and renin angiotensin blockers.

Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Coronary stent or bypass 10 years ago or more.
3. Dependable mental status to recall events.

Exclusion Criteria:

1. Non coronary operations
2. Inability to recall evnets

Primary outcomes:
measure: Risk factors
timeFrame: Since index procedure to time of interview at least 10 years later
measure: Arterial revascularizations
timeFrame: Since index procedure to time of interview at least 10 years later
Secondary outcomes:
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Istishari Hospital
city: Amman
country: Jordan
facility: Specialty Hospital
Study officials:
References:
Clinical trial NCT05794022: Cohort of STEMI Patients 2
Official title: CoHort of Patients to Identify Biological and Imaging MarkerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Myocardial Infarction
Keywords: Myocardial infarction
bio-collection
Imaging markers
biomarkers
STEMI
clinical outcomes
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-03-31
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).

The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
* Management in primary ACT
* Prior oral informed consent followed by signed informed consent as soon as possible.

Exclusion Criteria:

* Diagnosis of STEMI not confirmed on angiography
* Inability to give the subject informed information
* Lack of coverage by a social security scheme
* Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR\<30 ml/min), known allergy to the contrast medium ....)
* Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman.
* Deprivation of civil rights (curators, guardianship, safeguard of justice)

Primary outcomes:
measure: Research of potential new markers
timeFrame: 1 year
Secondary outcomes:
measure: Calculation of infarct size on MRI
timeFrame: 1 month
measure: Pharmacoepidemiology of myocardial infarction.
timeFrame: 5 years
measure: Events between inclusion and 5 years follow-up
timeFrame: 5 years
Other outcomes:
Locations:
city: Bron
country: France
facility: Hospices Civils de Lyon - Hôpital Louis Pradel
state: Rhone
city: Lyon
country: France
facility: Hospices Civils de Lyon - Hôpital de la Croix Rousse
state: Rhone
Study officials:
References:
Clinical trial NCT02193139: Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
Official title: A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hyperhidrosis
Lead sponsor: Watson Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-07-17
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers with primary axillary hyperhidrosis
* Poor quality of life rating on the Hyperhidrosis Disease Severity Scale (score of 3 or 4)
* Has a baseline gravimetric measurement of spontaneous resting sweat production of ≥100 mg/10 min at room at room temperature in at least one axilla
* Meets at least two of the following criteria (self-reported):

  * sweating is bilateral and symmetrical
  * excessive sweating impairs daily activities
  * subject experiences at least one sweating episode per week
  * excessive sweating onset was earlier than age 25 years
  * has a positive family history for excessive sweating
  * cessation of sweating during sleep

Primary outcomes:
measure: Gravimetric measurement of sweat production
timeFrame: 6 weeks
Secondary outcomes:
measure: Hyperhidrosis Disease Severity Scale (HDSS) scores
timeFrame: 6 weeks
measure: Dermatology Life Quality Index (DLQI) scores
timeFrame: 6 weeks
measure: Global Assessment of Disease State responses
timeFrame: 6 weeks
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Watson Clinical Site
state: California
Study officials:
References: